Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer

References

• Mehta K, McQueen T, Neamati N, et al. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1996;7:179–86.
   PubMedGoogle Scholar
• Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous Panniculitis-Like T-Cell Lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk 2012;12:20–5.
   PubMed Web of Science ®Google Scholar
• Malik SM, Collins B, Pishvaian M, et al. A phase I trial of bexarotene in combination with Docetaxel in patients with advanced solid tumors. Clin Lung Cancer 2011;12:231–6.
   PubMed Web of Science ®Google Scholar
• Böhm BH, Müller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharm Sci Technol Today 1999;2:336–9.
   PubMedGoogle Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631–44.
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhang X, Zhang T, et al. Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique. Drug Dev Ind Pharm 2015;41:1416–24.
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. Twenty years of drug nanocrystals: where are we, and where do we go? Eur J Pharm Biopharm 2012;80:1–3.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125:91–7.
   Web of Science ®Google Scholar
• Neubert RH. Potentials of new nanocarriers for dermal and transdermal drug delivery. Eur J Pharm Biopharm 2011;77:1–2.
   PubMed Web of Science ®Google Scholar
• Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release 2010;141:277–99.
   PubMed Web of Science ®Google Scholar
• Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine 2011;7:242–7.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011;63:441–55.
   PubMed Web of Science ®Google Scholar
• Roa WH, Azarmi S, Al-Hallak MH, et al. Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J Control Release 2011;150:49–55.
   PubMed Web of Science ®Google Scholar
• Wei L, Ji Y, Gong W, et al. Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals. Drug Dev Ind Pharm 2015;41:1343–52.
   PubMed Web of Science ®Google Scholar
• Li W, Tian H, Li L, et al. Diallyl trisulfide induces apoptosis and inhibits proliferation of A549 cells in vitro and in vivo. Acta Biochim Biophys Sin 2012;44:577–83.
   Google Scholar
• Chen L, Wang Y, Zhang J, et al. Bexarotene nanocrystal—Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm 2014;87:160–9.
   PubMed Web of Science ®Google Scholar
• Zheng D, Wang Y, Zhang D, et al. In vitro antitumor activity of silybin nanosuspension in PC-3 cells. Cancer Lett 2011;307:158–64.
   PubMed Web of Science ®Google Scholar
• Subramaniam V, Ace O, Prud’homme GJ, Jothy S. Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol 2011;90:116–22.
   PubMed Web of Science ®Google Scholar
• Fotakis G, Timbrell JA. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006;160:171–7.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Shin JY, Kim JO, et al. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. Cancer Lett 2012;322:213–22.
   PubMed Web of Science ®Google Scholar
• Wang H, Li H, Zuo M, et al. Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett 2008;268:89–97.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Z, Zhang D, et al. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloids Surf B Biointerfaces 2011;83:189–97.
   PubMed Web of Science ®Google Scholar
• Hermann TW, Yen WC, Tooker P, et al. The retinoid X receptor agonist bexarotene(Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer 2005;50:9–18.
   PubMed Web of Science ®Google Scholar
• Qu L, Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 2009;65:201–5.
   PubMed Web of Science ®Google Scholar
• He C, Yin L, Tang C, Yin C. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials 2012;33:8569–78.
   PubMed Web of Science ®Google Scholar
• Spernath A, Aserin A, Ziserman L, et al. Phosphatidylcholine embedded microemulsions: Physical properties and improved Caco-2 cell permeability. J Control Release 2007;119:279–90.
   PubMed Web of Science ®Google Scholar
• Mathot F, van Beijsterveldt L, Préat V, et al. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release 2006;111:47–55.
   PubMed Web of Science ®Google Scholar
• Gamboa JM, Leong KW. In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev 2013;65:800–10.
   PubMed Web of Science ®Google Scholar
• Sandri G, Bonferoni MC, Rossi S, et al. Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur J Pharm Biopharm 2007;65:68–77.
   PubMed Web of Science ®Google Scholar